Martina Garau - OHE

We found for

International Cost-Effectiveness Thresholds and Modifiers for HTA Decision Making

Are Cost-Effectiveness Thresholds fit for Purpose for Real-World Decision Making?

Unrelieved Pain in Palliative Care in England

#image_title

How Should We Measure Quality of Life Impact in Rare Disease? Recent Learnings in Spinal Muscular Atrophy

Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward

R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C

Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence

Market Access

Comparing Access to Orphan Medicinal Products (OMPs) in the United Kingdom and other European countries

Policy Options for Formulary Development in Middle-income Countries

Policy Options for Formulary Development in Middle-income Countries: Mexico Case Study

Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)

$Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL) report cover$

Improving Efficiency and Resource Allocation in Future Cancer Care

Obstructive Sleep Apnoea: Health Economics Report

Exploring the Interdependencies of Research Funders in the UK

Exploring the link between health and wealth in decision making

Multi-Criteria Decision Analysis to Value Orphan Medicines

01
02
03

News & Insights

Latest Research & Publications

All Publications

We found for

Filter results by

International Cost-Effectiveness Thresholds and Modifiers for HTA Decision Making

Are Cost-Effectiveness Thresholds fit for Purpose for Real-World Decision Making?

Unrelieved Pain in Palliative Care in England

How Should We Measure Quality of Life Impact in Rare Disease? Recent Learnings in Spinal Muscular Atrophy

Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward

R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C

Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence

Comparing Access to Orphan Medicinal Products (OMPs) in the United Kingdom and other European countries

Policy Options for Formulary Development in Middle-income Countries

Policy Options for Formulary Development in Middle-income Countries: Mexico Case Study

Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)

Improving Efficiency and Resource Allocation in Future Cancer Care

Obstructive Sleep Apnoea: Health Economics Report

Exploring the Interdependencies of Research Funders in the UK

Exploring the link between health and wealth in decision making

Multi-Criteria Decision Analysis to Value Orphan Medicines

Share on Mastodon